TY - JOUR
T1 - Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer
AU - Bufi, Enida
AU - Belli, Paolo
AU - Di Matteo, Marialuisa
AU - Giuliani, Michela
AU - Tumino, Mariavalentina
AU - Rinaldi, Pierluigi
AU - Nardone, Luigia
AU - Franceschini, Gianluca
AU - Mule', Antonino
AU - Bonomo, Lorenzo
PY - 2016
Y1 - 2016
N2 - Micro-Abstract Asymmetric increase in breast vascularity (AIBV) is an emerging marker in magnetic resonance imaging-based evaluation of breast cancer. We analyze herein the largest series so far aimed at elucidating the potential role of AIBV in predicting the early and late outcomes of locally advanced breast cancer. We observed that, despite more aggressive pathologic profile of tumors associated with AIBV, they also present greater sensitivity to neoadjuvant chemotherapy. Nonetheless, the persistence of AIBV after neoadjuvant chemotherapy is associated with worse late prognosis and might be used to tailor additional treatments.
AB - Micro-Abstract Asymmetric increase in breast vascularity (AIBV) is an emerging marker in magnetic resonance imaging-based evaluation of breast cancer. We analyze herein the largest series so far aimed at elucidating the potential role of AIBV in predicting the early and late outcomes of locally advanced breast cancer. We observed that, despite more aggressive pathologic profile of tumors associated with AIBV, they also present greater sensitivity to neoadjuvant chemotherapy. Nonetheless, the persistence of AIBV after neoadjuvant chemotherapy is associated with worse late prognosis and might be used to tailor additional treatments.
KW - Breast tumor
KW - Cancer Research
KW - Increased vascularization
KW - Magnetic Resonance Imaging
KW - Neoadjuvant chemotherapy
KW - Oncology
KW - Prognosis
KW - Breast tumor
KW - Cancer Research
KW - Increased vascularization
KW - Magnetic Resonance Imaging
KW - Neoadjuvant chemotherapy
KW - Oncology
KW - Prognosis
UR - https://publicatt.unicatt.it/handle/10807/91621
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84995630319&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84995630319&origin=inward
U2 - 10.1016/j.clbc.2016.06.007
DO - 10.1016/j.clbc.2016.06.007
M3 - Article
SN - 1526-8209
VL - 16
SP - e193-e201
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 6
ER -
